SoluPath screening includes non-GMP formulation utilising five different drug delivery modalities
Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, will feature its paradigm changing SoluPath service offering at the CPhI Conference, which runs from 13 – 15 July 2011 in Osaka, Japan. This fixed price service offering is designed to improve bioavailability of compounds with poor solubility by testing, in parallel, multiple formulations.
SoluPath screening includes non-GMP formulation utilising five different drug delivery modalities: micronisation, nanoparticles, lipid-based solutions, co-solvent solutions SMEDDS/SEDDS, and spray drying. By screening multiple cutting edge technologies in parallel, SoluPath delivers rapid results and identifies the best drug delivery solution to increase bioavailability in human studies.
Patheon’s Dr. Kenji Yamada will talk about the SoluPath process during his presentation on 13 July at 11:30 a.m. in Room A. Patheon representatives will also be available to discuss the company’s new service offering at Booth F14 through the duration of the conference.